Administration of anti-receptor activator of nuclear factor-kappa B ligand (RANKL) antibody for the treatment of osteoporosis was associated with amelioration of hepatitis in a female patient with growth hormone deficiency: a case report
Open Access
- 24 November 2016
- journal article
- case report
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 16 (1) , 1-4
Abstract
Growth hormone deficiency (GHD) is associated with non-alcoholic fatty liver disease (NAFLD). A recent animal study showed that hepatocyte-specific receptor activator of nuclear factor-kappa B (RANK) knockout mice had significantly lower liver fat content compared with control mice concomitant with a decrease in production of inflammatory cytokines such as tumor necrosis factor-α (TNF-α) from hepatocytes and kupffer cells. The role of anti-RANK ligand (RANKL) antibody for osteoporosis on hepatitis in patients with aGHD is still unknown. A forty-seven-year-old female patient was referred to our hospital to investigate chronic hepatitis caused by unknown etiology. She had past history of craniopharyngioma treated with craniotomy and post-surgical radiotherapy. She was for the first time diagnosed as panhypopituitarism including growth hormone deficiency and osteoporosis by endocrine examinations and bone mineral densitometry, respectively. In addition, non-alcoholic steatohepatitis (NASH) was histologically confirmed by liver biopsy in this time. Sixty mg anti-RANKL antibody, which was subcutaneously injected to treat the osteoporosis every six months after replacement of 5 mg hydrocortisone and 30 μg oral desmopressin, rapidly decreased the levels of her liver enzymes (ALT and γGTP were 133 to 72 U/L and 284 to 99 U/L at 16 months after the beginning of the treatment, respectively). Additional amelioration of liver dysfunction was not observed after growth hormone replacement. The clinical course of the present case suggested that RANKL-RANK signaling may be a key pathological mechanism in establishment or development of NAFLD or NASH in patients with panhypopituitarism including GHD.Keywords
This publication has 13 references indexed in Scilit:
- The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)Metabolism, 2016
- Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiencyGrowth Hormone & IGF Research, 2014
- Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitusNature Medicine, 2013
- Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapyEuropean Journal of Endocrinology, 2012
- Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High RiskThe Journal of Clinical Endocrinology & Metabolism, 2011
- The role of cytokines in non-alcoholic steatohepatitis. A review.2006
- Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiencyGut, 2003
- Animal models of steatohepatitisBest Practice & Research Clinical Gastroenterology, 2002
- Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKLProceedings of the National Academy of Sciences, 1998
- Effect of growth hormone on fatty liver in panhypopituitarismArchives of Disease in Childhood, 1997